Agreed and well said. Let me just add that I'm thinking that a BP player who licenses our wonder drug could enhance their own fortunes by introducing LL as (1) a standalone or (2) as a combo therapy thereby increasing the utility of their own drug, getting a new patent for the combo therapy, and then lengthening the stay and ROI of the original treatment (their original drug) on the market via the combo therapy.

This route helps both the patient and the bottom line. Much better than letting your competitors get their hands on a superior drug to treat a specific indication.

To a creative CEO like Dr L, the objective of helping the human condition as well as taking care of the shareholders can be in harmony with each other. There has to be a creative BP CEO out there who sees that as well